Navigation Links
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Date:2/29/2008

hich speak only as of their dates. These forward- looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.

The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facility; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in t
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
6. Cepheid Reports Fourth Quarter and Full Year 2007 Results
7. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
8. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
9. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
10. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
11. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Donald Fresne, President and ... of Stephan Vagner , PhD to its Scientific Advisory ... of Toulouse, France , performed research at ... , and at Inserm, the French institute of health and ... works both at the Curie Institute, Orsay, France ...
(Date:9/16/2014)... Oro Valley, Arizona (PRWEB) September 16, 2014 ... company that develops safe and effective products to ... through the use of a proprietary SPACEā„¢ Technology ... Executive Officer and President will present at the ... 18, 2014 at the Hyatt Regency Phoenix. ...
(Date:9/16/2014)... 2014 BCC Research reveals in ... CELLS , the global market for stem cells is ... with a five-year compound annual growth rate (CAGR) of ... Americas with growth projections of $2.2 billion in 2014 ... http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other potential applications of ...
(Date:9/15/2014)... Cancer Immunotherapy Market : Immune ... is a new market research report announced by ... types of therapeutics that have become the major ... (which is often called "immuno-oncology") in recent years: ... immunotherapy. , The regular use of immunotherapy ...
Breaking Biology Technology:New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5
... Q4 2007 sales increased 78.8% compared to Q4 2006 -- ... Estimated sales for FY ... increased 89.4% compared to FY 2006, NEW YORK, March ... a leading provider in the,nutraceutical industry engaged in the development, ...
... WELLESLEY HILLS, Mass., March 5 Joseph F. Finn, ... ActivBiotics, confirmed,today that the sale of ActivBiotics, proprietary assets ... PM on March 14, 2008. There has been,substantial interest ... 48 bid packages being reviewed by companies, in addition,to ...
... NEW YORK, March 5 Bristol-Myers Squibb,Company (NYSE: ... Board of Directors,has elected Jean-Marc Huet senior vice ... In this role, Mr. Huet will be,responsible for ... as the global financial operations of the organization ...
Cached Biology Technology:China Yingxia International Announces Q4 and FY 2007 Estimates 2China Yingxia International Announces Q4 and FY 2007 Estimates 3Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3
(Date:9/16/2014)... . CRG researchers ... Journal of Cell Biology describes how Topo 2 ... , At this very moment thousands of our body,s cells ... the body repairs damaged tissues and regenerates others like skin ... "mitosis", during which the cell duplicates its genetic material and ...
(Date:9/16/2014)... Exxon Valdez spilled 11 million gallons of oil into ... another giant oil spill in the Gulf of Mexico ... Journal of Consumer Research , news coverage of ... of catalyzing changes in the way fossil fuels are ... coverage of these two events helped to resolve many ...
(Date:9/16/2014)... , Sept. 16, 2014  Valencell, Inc., a ... chosen as one of 18 "Showcase Companies" representing ... at the annual CED Tech Venture Conference on September ... Convention Center in Raleigh, North Carolina ... will lead a discussion during the "Digital Health Spotlight ...
Breaking Biology News(10 mins):Unraveling cell division 2Unraveling cell division 3Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2
... 1, 2011 Tiny marine organisms called zooplankton can use ... areas of the ocean where oxygen levels are so low ... trouble as these areas expand due to climate change. ... said University of Rhode Island doctoral student Leanne Elder. "But ...
... 2011 (Bronx, NY) A longstanding medical mystery ... other cognitive problems despite potent antiretroviral therapy may have ... of Yeshiva University. Their findings are published in the June ... Even though antiretroviral treatment suppresses HIV replication and slows ...
... study co-authored by University of Florida researchers provides details on ... concern as warm summer waters attract more people to the ... July print edition of Pacific Science warns that ... may be considered prey. The sharks feed near ...
Cached Biology News:Climate change could turn oxygen-free seas from blessing to curse for zooplankton 2New study documents first cookiecutter shark attack on a live human 2New study documents first cookiecutter shark attack on a live human 3
...
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
... NPY Y2 Receptor antiserum This NPY ... spinal level and is currently being characerized in ... rat and mouse and appears to work better ... in rat. For full characterizarion in dorsal root ...
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
Biology Products: